| cardiovascular prevention | anacetrapib | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| REALIZE, 2015 | anacetrapib vs placebo | | | cardiovascular events ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| REALIZE, 2015 | oral anacetrapib 100 mg for 52 weeks (n=204) vs. placebo (n=102) | patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease | double-blind Parallel groups Sample size: 204/102 Primary endpoint: percentage change from baseline in LDL-C FU duration: 52 weeks |
|
| cardiovascular prevention | anacetrapib | not classified | versus placebo No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| DEFINE, 2010 | anacetrapib vs placebo | | | all cause death 1.38 [0.56; 3.40] Cardiovascular death 4.00 [0.45; 35.76] Nonfatal stroke 1.00 [0.29; 3.45] Nonfatal myocardial infarction 0.67 [0.24; 1.87] Cardiovascular death, myocardial infarction, stroke 0.76 [0.40; 1.45] cardiovascular events 0.76 [0.40; 1.45] |
| Trial | Treatments | Patients | Method |
|---|
| DEFINE, 2010 | anacetrapib 100mg fr 18 months (n=811) vs. placebo (n=812) | patients with coronary heart disease or at high risk for coronary heart disease | double-blind Parallel groups Sample size: 811/812 Primary endpoint: percent change from baseline in LDL cholesterol at 24 weeks FU duration: |
|
| cardiovascular prevention | torcetrapib | not classified | versus placebo No demonstrated result for efficacy torcetrapib inferior to placebo in terms of all cause death in ILLUMINATE, 2007 torcetrapib inferior to placebo in terms of Coronary revascularization in ILLUMINATE, 2007 | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| RADIANCE 1, 2007 | torcetrapib vs placebo | | | all cause death 0.00 [0.00; NaN] Cardiovascular death 0.00 [0.00; NaN] Nonfatal stroke 1.01 [0.06; 16.08] Nonfatal myocardial infarction ∞ [NaN; ∞] | | ILLUMINATE, 2007 | torcetrapib vs placebo | | all cause death 1.58 [1.14; 2.18] Coronary revascularization 1.25 [1.10; 1.42] | CHD death 1.21 [0.77; 1.92] coronary events 1.22 [0.98; 1.51] Cardiovascular death 1.40 [0.91; 2.16] Nonfatal myocardial infarction 1.20 [0.94; 1.53] stroke 1.08 [0.70; 1.65] Cardiovascular death, myocardial infarction, stroke 1.16 [0.95; 1.40] | | RADIANCE 2, 2007 | torcetrapib vs placebo | | | | | ILLUSTRATE, 2007 | torcetrapib vs placebo | | | all cause death 1.35 [0.47; 3.86] CHD death 1.01 [0.06; 16.11] Nonfatal myocardial infarction 0.82 [0.40; 1.69] stroke 0.25 [0.05; 1.18] Coronary revascularization 1.21 [0.95; 1.55] |
| Trial | Treatments | Patients | Method |
|---|
| RADIANCE 1, 2007 | atorvastatin combined with 60 mg of torcetrapib (n=450) vs. atorvastatin monotherapy (n=454)
| patients with heterozygous familial hypercholesterolemia
| open Parallel groups Sample size: 450/454 Primary endpoint: carotid intima–media thickness FU duration: 24 months
| | ILLUMINATE, 2007 | torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) (n=7533) vs. atorvastatin alone (n=7534) | patients at highcardiovascular risk | double blind Parallel groups Sample size: 7533/7534 Primary endpoint: MACE FU duration: 1.52y | | RADIANCE 2, 2007 | torcetrapib 60mg daily (on top of atorvastatin attitrated dose) (n=377) vs. placebo +atorvastatin attitrated dose (n=375) | patients with mixed dyslipidaemia | double blind Parallel groups Sample size: 377/375 Primary endpoint: maximum intima-media thickness of 12 carotid segments FU duration: 24 months | | ILLUSTRATE, 2007 | atorvastatin plus 60 mg of torcetrapib daily (n=591) vs. atorvastatin monotherapy (n=597) | patients with coronary disease | open Parallel groups Sample size: 591/597 Primary endpoint: intravascular ultrasonography FU duration: 24 months |
|
